|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 溃疡性结肠炎药物治疗的研究进展显示文摘溃疡性结肠炎(ulcerative colitis,UC)作为一种自身免疫性疾病,其发生及发展机制尚未明确,但相关研究表明免疫因素在UC发生、发展及愈后的过程中起重要作用。关于UC的治疗,临床常用的方法是药物治疗,其中免疫抑制剂及生物制剂在中、重度UC的治疗中起重要作用。本文主要对近年来国内外有关新型免疫抑制剂及生物制剂在UC治疗方面的疗效作一概述。 | 李明明 王启之 | 2017 | 胃肠病学和肝病学杂志2017，26，4： | 26 |
| 2 | Inflammatory bowel disease unclassified显示文摘Objective:Inflammatory bowel diseases (IBDs) are idiopathic,chronic,and inflammatory intestinal disorders.The two main types,ulcerative colitis (UC) and Crohn's disease (CD),sometimes mimic each other and are not readily distinguishable.The purpose of this study was to present a series of hospitalized cases,which could not initially be classified as a subtype of IBD,and to try to note roles of the terms indeterminate colitis (IC) and inflammatory bowel disease unclassified (IBDU) when such a dilemma arises.Methods:Medical records of 477 patients hospitalized due to IBD,during the period of January 2002 to April 2009,were retrospectively studied in the present paper.All available previous biopsies from endoscopies of these patients were reanalyzed.Results:Twenty-seven of 477 IBD patients (5.7%) had been initially diagnosed as having IBDU.Of them,23 received colonoscopy and histological examinations in our hospital.A total of 90% (9/10) and 66.7% (4/6) of patients,respectively,had a positive finding via wireless capsule endoscopy (CE) and double-balloon enteroscopy (DBE).The barium-swallow or small bowel follow-through (SBFT) was performed on 11 patients.Positive changes were observed under computer tomographic (CT) scanning in 89.5% (17/19) of patients.Reasonable treatment strategies were employed for all patients.Conclusions:Our data indicate that IBDU accounts for 5.7% of initial diagnoses of IBD.The definition of IBDU is valuable in clinical practice.For those who had no clear clinical,endoscopic,histological,or other features affording a diagnosis of either UC or CD,IBDU could be used parenthetically. | Ning ZHOU Wei-xing CHEN Shao-hua CHEN Cheng-fu XU You-ming LI | 2011 | Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)2011，12，4： | 5 |
| 3 | 高效免疫抑制剂在炎性肠病中的应用显示文摘目的:探索高效免疫抑制剂在IBD方面的疗效、耐受性及不良反应。方法:以大样本、开放式、随机选择300例中重度溃疡性结肠炎(UC)并将其分为三组,分别观察吗替麦考酚酯、他克莫司、环孢菌素A的疗效差异、耐受性与不良反应率。结果:三组患者的疾病活动指数(Sutherland DAI)分别从8.70下降至3.53,8.68下降至3.77,7.64下降至4.81(P<0.001)差异有统计学意义。内镜下完全缓解率分别是60%、52%、45%,疗效显著。不耐受掉队者和不良反应分别是9%、30%、10%,但其不良反应都是可逆性的。结论:揭示高效免疫抑制剂对IBD有卓越的疗效并且具有较好的安全性,为IBD的药疗提供了又一条途径。 | 徐子鹏 胡金玉 | 2013 | 吉林医学2013，34，13： | 2 |
| 4 | 免疫抑制剂治疗 IBD 的不良反应及对策显示文摘炎症性肠病( inflammatory bowel disease,IBD)是一组慢性非特异性肠道炎症性疾病,主要包括溃疡性结肠炎( ulcerative colitis,UC)和克罗恩病( Crohn’s disease,CD)。IBD 在国外尤其是欧洲和北美发病率较高,随着人民生活水平的提高、饮食结构的改变和社会环境的变化以及诊断水平提高,近年来在我国的发病率呈逐年上升的趋势。 | 李瑾 邓长生 赵秋 | 2015 | 医学新知2015，25，4： | 0 |
| 5 | What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?显示文摘The inflammatory bowel diseases(IBDs) are chronic incurable conditions that primarily present in young patients. Being incurable, the IBDs may be part of the patient's life for many years and these conditions require therapies that will be effective over the long-term. Surgery in Crohn's disease does not cure the disease with endoscopic recurrent in up to 70% of patients 1 year post resection. This means that, the patient will require many years of medications and the goal of the treating physician is to induce and maintain long-term remission without side effects. The development of the antitumour necrosis factor alpha(TNFα) agents has been a magnificent clinical advance in IBD, but they are not always effective, with loss of response overtime and, at times, discontinuation is required secondary to side effects. So what options are available if of the anti-TNFα agents can no longer be used? This review aims to provide other options for the physician, to remind them of the older established medications like azathioprine/6-mercaptopurine and methotrexate, the less established medications like mycophenolate mofetil and tacrolimus as well as newer therapeutic options like the anti-inte-gins, which block the trafficking of leukocytes into the intestinal mucosa. The location of the intestinal inflammation must also be considered, as topical therapeutic agents may also be worthwhile to consider in the longterm management of the more challenging IBD patient. The more options that are available the more likely the patient will be able to have tailored therapy to treat their disease and a better long-term outcome. | Ian C Lawrance | 2014 | World Journal of Gastroenterology2014，20，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员